HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Public ClinicalTrials.gov record NCT05176691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
Study identification
- NCT ID
- NCT05176691
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2022
- Primary completion
- Nov 15, 2022
- Completion
- Nov 15, 2022
- Last update posted
- Feb 20, 2023
2022
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Innovative Clinical Research | Anaheim | California | 92801 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| Johns Hopkins Clinical Research Center | Baltimore | Maryland | 21287 | — |
| AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company | Kansas City | Missouri | 64114 | — |
| Center For Advanced Medicine | St Louis | Missouri | 63110 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932 | — |
| New York University Langone Med Center. Lab | New York | New York | 10016 | — |
| Clinical Research Alliance | Westbury | New York | 11590 | — |
| Renovatio Clinical | El Paso | Texas | 79915 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| Renovatio Clinical | The Woodlands | Texas | 79915 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
Recently updated CLL/SLL trials
Other public records listing CLL/SLL. Sorted by last update posted; newest first. Not a recommendation.
- NCT07342478: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Recruiting
- NCT04775745: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Recruiting
- NCT07108998: Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Recruiting
- NCT06708897: A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas Recruiting
- NCT06104566: Global Trial in APG2575 for Patients With CLL/SLL Recruiting
- NCT06978088: LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05176691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2023 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05176691 live on ClinicalTrials.gov.